NCT04951219Phase 3Active not recruiting

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Study sponsor: Madrigal Pharmaceuticals, Inc. · MDGL

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-03Estimated
Enrollment · participants810Actual
Source updated2026-05-27Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 1000 participants (planned). After: 810 participants (actual).

Primary completion date changed

Before: Mar 2026. After: Mar 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview